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Myofibrillar proteins constitute about 50-55% of total protein in muscle cells. 
Studies of the mechanism of turnover of these proteins under normal physiological 
conditions can be applied to 3 areas: meat production (muscle cell growth), meat industry 
(tenderization), and therapy of muscle diseases. Three intracellular proteolytic systems may 
be involved in myofibrillar protein turnover, including lysosomal cathepsins, calpains, and 
the multicatalytic protease complex (proteasome). Previous studies have indicated that 
lysosomal system is not important in myofibrillar protein turnover. In contrast, the calpain 
system appears to play an important role for intracellular myofibrillar protein  turnover. 
However, the effect of the proteasome on turnover of this pool of protein remains uncertain. 
The goal of this study was to use protease inhibitors to distinguish the function of calpains 
and the proteasome muscle protein degradation. 
In this study five different protease inhibitors were used in cultured rat muscle cells 
(L8 cell line), to assess the function of individual proteolytic species in myofibrillar protein 
degradation. All inhibitors, with the exception of PD150606, reduced total protein 
degradation (TPD) in cultured myotubes. At inhibitors' maximal effects, CI-II (75 [tM) 
Redacted for Privacyreduced TPD by 52%, CA reduced TPD by 44%, LACT reduced TPD by 26%, and  ZIE 
reduced TPD by 53%. Although each of these inhibitors strongly reduced TPD, their 
abilities to reduce myofibrillar protein degradation were variable. At their maximal effects, 
CI-II reduced myofibrillar proteins degradation by 32%, ZIE decreased degradation of the 
same pool by 27%, and CA decreased degradation of this pool by 17%. LACT, a potent and 
specific proteasome inhibitor had no effect on myofibrillar protein degradation. 
We found that inhibitors which inhibited calpains stabilized the myofibrillar pool yet 
proteasome specific inhibitor (lactacystin) had no effect on this pool, however lactacystin 
caused accumulations of ubiquitinated protein. CI-II stabilized the myofibrillar pool but did 
not caused Ub-protein complex accumulation. From this, it seems clear that calpain play key 
roles in coordination of myofibrillar protein degradation. 
These data indicate that control of calpain activities in vivo may be useful in treating 
muscle diseases and in enhancing muscle growth of domestic animals. Effects of Various Protease Inhibitors on Protein Degradation of Cultured Myotubes 
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 EFFECTS OF VARIOUS PROTEASE INHIBITORS ON PROTEIN
 
DEGRADATION OF CULTURED MYOTUBES 
INTRODUCTION 
Myofibrillar proteins constitute about 50-55% of total protein in muscle cells (Goll 
et al., 1989). Studying the degradation of this pool is important to three different fields: meat 
production (muscle cell growth), the meat industry and therapeutic clinical usage. The basic 
knowledge of the involvement and regulation of three intracellular proteinase systems, 
including lysosomal cathepsins, Ca2+-dependent neutral protease (calpains), and 
multicatalytic protease complex (proteasome) are therefore of research and clinical interest. 
Net growth of muscle tissue depends on both muscle protein synthesis and muscle 
protein degradation. In growing animals, synthesis and degradation tend to move in parallel, 
with synthesis rate exceeding degradation rate. It is estimated that to maintain muscle mass, 
the muscle would have to synthesize an amount of protein equivalent to 5 to 10 percent of its 
protein content on a daily basis (Allen,  1988). Hence inhibition of muscle protein 
degradation could cause a dramatic change in rate of muscle growth. Although cathepsins 
are found in muscle and have activities on myofibrillar protein substrates (Goll et al.,  1983; 
Matsuishi et al.,  1992), little evidence indicates correlation between lysosomal enzyme 
activities and myofibrillar protein degradation. Non-lysosomal proteases are therefore more 
likely to be responsible for myofibrillar protein degradation. 
Summarizing from more than 30  various experiments, Goll et al (1989) have 
proposed a possible mechanism which indicates that calpain is responsible for at least the 
initial step or the rate-regulating step of myofibrillar protein degradation. The calpains can degrade Z-disks and C-protein rings from the thick filaments and troponins T, I, and 
tropomyosin from thin filaments. This is proposed to result in loosening of myosin molecules 
on the surface of the thick filaments and the actin molecules constituting the thin filaments, 
so they are released into the surrounding sarcoplasm. After dissociation into monomers and 
dimers, the actin and myosin molecules are proposed to be further degraded by other 
proteases, or reincorporated into myofibrillar proteins (Goll et al., 1989). Although evidence 
supports the idea that calpains are responsible for myofibrillar protein degradation, the 
cause-and-effect relationship has not been unequivocally proven yet. 
The multicatalytic protease complex (proteasome) in vitro can break down the most 
abundant myofibrillar proteins: actin and myosin, through a ubiquitin-independent pathway, 
in a slow manner (Richard et al., 1995). The proteasome can also degrade protein through a 
ubiquitin-dependent pathway (Dahlmann and Kuehn, 1995). Involvement of the proteasome 
in myofibrillar protein degradation, however has been observed mostly in diseases or other 
abnormal conditions, such as heat-shock (Wing et al., 1993) or denervation (Furuno et al., 
1990). Additional evidence that proteasome may be involved in myofibrillar protein 
degradation is that the branched-chain amino acid preferring (BrAAP) activity of 
proteasome can be activated by Ca2' (Orlowski et al., 1992). Calcium has been implicated 
be the etiology of numerous muscle diseases and it is therefore possible that it acts via 
BrAAP activity of proteasome rather than via calpains. Another evidence that proteasome 
may be involved in myofibrillar protein degradation is that proteasome is also active at 
normal cytosolic pH (Orlowski et al., 1992). 
In the meat industry, one of the factors which determines palatability of meat is its 
tenderness. Intracellular degradation of myofibrillar proteins is closely related to postmortem tenderization (Troy et al., 1986, 1987; Koohmaraie et al., 1987). Calpain is 
suspected to be the major protease involved in postmortem meat tenderization because of 
several observations: 1) the intracellular Cat' concentration increases postmortem, 2) 
cathepsin activities decline, and 3) calpain cannot degrade cc-actin and myosin heavy chains, 
which remain intact postmortem (Jeacocke, 1993; Honikel et al., 1983; Hertzman et al., 
1993). 
In human and animal health, many diseases result in rapid muscle wasting. Examples 
include denervation (Furuno et al., 1990), sepsis, diabetes mellitus, malnutrition, cancer 
(Temparis et al., 1994), acidosis (Mitch et al., 1994), and genetic muscular dystrophies 
(Richard et al., 1995). Beside alterations in transcription and translation of myofibrillar 
proteins, the increased catabolic process is the major reason for rapid muscle wasting under 
these conditions. 
There are four general methods currently used to study regulation and activity of 
muscle intracellular proteases: 1) Incubate purified proteins or synthesized oligopeptides 
with a fully- activated purified single protease, in the presence of an activators or inhibitors, 
followed by microscopic examination of the morphological changes of the tissue. Most data 
of substrate specificity and optimal conditions for protease activities has been obtained in 
this manner (Busch et al., 1972; Dayton et al  1976; Taylor et al., 1995). The drawback of 
this approach is that the true action of proteases is not revealed, since the proteases  are 
always fully activated by unnatural factors, such as using extremely high Cat` concentration 
to activate calpains, or adding SDS to activate proteasomal activities. 
2) Create an abnormal body condition which will stimulate muscle protein degradation, such 
as sepsis (Tiao et al., 1994), denervation (Furuno et al., 1990), starvation (Medina, 1995), 4 
tumor (Temparis et al., 1994), or heat shock (Mykles, 1993), and examine the intracellular 
protease mRNA concentration and protease activity or the expression of their regulators. 
This approach can reflect the responses to certain physiological changes in living animals. 
This method and the previous method do not reveal the nature of proteolysis in normal 
physiological conditions. 
3) Add certain protease inhibitors into cultured muscle cells and then analyze their effects on 
intracellular protein degradation. This will show the outcome of the event when a certain 
proteolytic pathway is blocked. Although this method may more precisely differentiate the 
functions of distinct protease systems, a limitation occurs since non-specificity of inhibitors 
make data interpretation difficult. Furthermore, cell permeability of the inhibitor, cell 
viability and intracellular stability of the cell can also be sources of problems. 
4) Directly block intracellular protease expression or overexpress inactive proteases and 
examine cell function. This approach is more specific and, supposedly, less uncertainty in 
interpretation results when compared with the other approaches. Although this approach 
needs more sophisticated experimental design and delicate techniques, this method holds 
promise for the future. 
In a series of experiments outlined in this thesis, we used the third method to analyze 
the roles of distinct proteases in normal physiological myofibrillar protein turnover. Our goal 
was to identify the function of individual proteolytic systems in normal turnover of 
myofibrillar proteins in cultured muscle cells. 5 
LITERATURE REVIEW 
Muscle, Ultrastructure of Muscle 
Skeletal muscle constitutes the largest protein-bound nitrogen pool in animal body 
(Young, 1970; Water low et al., 1978). It is essential for locomotion and in starvation, it 
serves as an important source of gluconeogenic carbon and essential amino acids for 
synthesis of crucial molecules. Animal skeletal muscle is the major source of high quality 
proteins in human diet. In human and animal health, skeletal muscle is subjected to several 
diseases which result in weakness, dysfunction of muscles or premature death, including 
genetic muscular dystrophies (Worton, 1995), Cushing's syndrome (Kayali et al., 1987), 
denervation (Furuno et al., 1986), disuse (Munoz et al., 1993), hyperthyroidism (Haysahi et 
al., 1986), and sepsis (Hasselgren and Fischer, 1992). 
The size of skeletal muscle cells can be very large: 2 or 3 cm long and 100 p.m in 
diameter in an adult human, and are often referred to as muscle fiber because of their highly 
elongated shape. Each one is syncytium, containing many nuclei within a common 
cytoplasm. The major part of intracellular protein mass in skeletal muscle is composed of 
myofibrils, which are the contractile elements of the muscle cell. Myofibrils are cylindrical 
structures of 1 to 2 [tm in diameter and are often as long as the muscle cell up to several 
centimeters. Each myofibril consists of a chain of tiny contractile units , or sarcomeres, each 
about 2.2 j_tm long, which give the vertebrate myofibril a striated appearance. 
An intact myofibril is composed of many proteins including 1) contractile force-
generating proteins: myosin heavy chain and light chains, and a-actin, where contraction 
occurs; 2) contraction regulatory proteins: tropomyosin, troponins I, C, and T, which 6 
response to Ca2- regulation of muscle contraction; and 3) accessory proteins: titin and 
nebulin, as framework of thick and thin filaments, respectively, maintain the architecture of 
the myofibril and provide it with elasticity; desmin (intermediate filaments), filamin, 
dystrophin, and ankyrin and binding individual myofibrils together or linking them to the 
sarcoplasmic membrane (Alberts et al., 1994; Taylor et al., 1994) 
Muscle Growth 
It was established about 50 years ago that the accumulation of muscle or muscle 
growth depends on both the rate of muscle protein synthesis and the rate of muscle protein 
degradation (Schoenheimer and Rittenberg, 1940). In addition, the number of muscle cells, 
which is determined by genetic trait of prenatal growth of myogenic cells, decides the 
capacity for protein accumulation (Allen et al., 1988). 
A mammalian skeletal muscle cell originates from mesodermal stem cells during 
embryogenesis through mechanisms that remain undefined. The myogenic lineage stem cells 
(myoblasts) can either remain in an undifferentiated state or be triggered to begin the events 
of terminal differentiation by extracellular cues. Activation of differentiation program is 
contingent upon cessation of cell division and is accompanied by the expression of an array 
of unlinked muscle-specific genes and fuse to form multinucleated myotubes (Goldspink et 
al., 1974). The mature muscle cell contains a large number of characteristic proteins, 
including specific types of actin, myosin, tropomyosin and troponin, creatine phospho-
kinase, and acetylcholine receptors (Alberts et al., 1994). 
Some commercially available skeletal muscle cell lines also synthesize muscle 
specific proteins characteristic of muscle tissue: examples are L8 and C2C p (ATCC 1992) 7 
thus making them good models of studying muscle growth. In a proliferating myoblast, 
these muscle-specific proteins and their mRNAs are absent or are present in very low 
concentrations. As myoblast begins to fuse with one another, the corresponding genes are 
switched on coordinately as part of a general transformation ofthe pattern of gene 
expression (Ou, 1995). 
In recent years, the cellular and molecular mechanisms involved in the regulation of 
skeletal-muscle development have gradually been revealed, including transcription factors 
(MyoD family), cell surface receptors (e.g. IGF receptors, thyroid hormone  receptors) and 
signal transduction pathways (protein kinase C, cAMP-dependent protein kinase, mitogen­
activated protein kinase). Environmental stimulation, such as innervation (Engel et al., 1974; 
Burden, 1993) and peptide growth factors (reviewed in Olson,  1992) exert dramatic effects 
on muscle gene expression. The most investigated transcription factors associated with 
muscle differentiation are grouped as MyoD family. Members of this family, which include 
MyoD, myf-5, myogenin, and MRF4, control myogenesis and serve as targets for a variety 
of environmental signals. Like many nuclear regulatory factors, members of the MyoD 
family positively autoregulate their own expression and cross-activate each others' 
expression (Braun et al., 1989). These regulatory interactions may confer stability to the 
myogenic phenotype and reinforce the decision to differentiate. They share sequence 
homology for the basic helix-loop-helix (bHLH) regulatory motif that mediate dimerization 
with another ubiquitously-expressed HLH protein families, such  as the E2A gene 
alternatively-splicing products (E12 and E47). A possible regulatory pathway is depicted as 
this: the functional heterodimer MyoD-E2A, which is negatively regulated by Id (inhibitor of 
differentiation) and oncogene product (c-fos, c-jun), will bind to a muscle specific enhancer 8 
DNA sequence - E box motif, with stabilization of retinoblastoma gene product (pRB) to 
activate the expression of muscle-specific genes (Dias et al., 1994; Olson, 1993). 
Phosphorylation of threonine at basic region of MyoD by protein kinase C or other kinases 
shows inhibition of dimerization (Skapek et al., 1995). Growth factors such as Fibroblast 
Growth Factor (FGF) and Tumor Growth Factor (TGF) are found to partially or fully block, 
depending on the cell line, the expression of the MyoD family, as well as inhibit activities of 
these regulatory factors in cells that express them constitutively (Olson, 1991). In fact, this is 
the principle to bring cultured myoblasts, such as rat skeletal muscle cell lines L8 and C2C12, 
to differentiation and fuse to form mature muscle cells (Yaffe and Saxel, 1977). 
The mature muscle cells both in living animals and cell culture systems are in a state 
of dynamic adaptation in response to hormones, mechanical activity and motor innervation 
(Allen et al., 1988). These factors modulate gene expression and splicing during this 
acclimation. Many factors have been studied for their effect on protein turnover and 
accretion. Insulin acutely stimulates protein synthesis at the level of translation by 
enhancing peptide-chain initiation (reviewed in Goll et al., 1989). Overall protein 
degradation is inhibited by insulin, but myofibrillar proteins appear insensitive to it. 
Insulin-like growth factors, or IGFs are potential paracrine and autocrine regulators of 
growth (Sara et al., 1990; Hong and Forsberg, 1994). In cultured skeletal muscle cells, 
physiological concentrations of IGF-1 and IGF-2 stimulate protein synthesis and inhibit 
degradation (Sara et al., 1990; Hong and Forsberg, 1994). It is suggested that the inhibition 
of protein degradation may be through down-regulation of proteasome activity (Hong and 
Forsberg, 1994). Dietary administration or injection of the 2-adrenergic agonist clenbuterol 
into rats stimulates skeletal muscle protein and RNA accretion in vivo and induces muscle 9 
fibre hypertrophy (Reeds, 1986). Studies have shown that these compounds regulate both 
protein synthesis and protein degradation and thereby increase accretion (Bards ley et al., 
1992). It has been known for a long time that thyroid hormones have a very significant role 
in skeletal muscle formation (Scow, 1953). A recent study indicated that thyroid hormone, 
mediated by thyroid hormone receptors and retinoid X receptors, promotes expression of 
myoD family and contractile protein genes, involving muscle differentiation and muscle type 
transition (Muscat et al, 1995). Glucocorticoid hormones's effect on muscle usually 
depends on insulin levels. Dexamethasone, a synthetic glucocorticoid, stimulates protein 
degradation in cultured L8 myotubes(Hong and Forsberg, 1995). In vivo, glucocorticoid 
activate protein degradation and cause muscle wasting (Kettelhut et al., 1988). 
Proteases 
In general, proteases have been classified into four families by the nature of their 
catalytic active site (based on Seemuller et al., 1995b): 1)Serine protease: examples 
including trypsin and chymotrypsin. In serine proteases, the hydroxyl group of serine 
constitutes the nucleophile and histidine and aspartic acid serve as proton donors to create 
the catalytic triad (Philipps and Fletterick, 1992). 2) Cysteine proteases, including calpain 
and papain, similar to serine proteases, the catalytic triad consists of an active site cystine as 
nucleophilic-attacking center, a histidine residue as proton donor, and an amino acid residue 
providing the oxyanion binding site (Sorimachi et al., 1995). 3) metallo-proteases, the 
nucleophilic attack is made by the carboxyl group of a glutamate or aspartate via a bound 
water molecule, while the metal ions, typically Zn2+, form the oxyanion binding site. 
4)aspartic proteases including pepsin and HIV protease, the nucleophilic attack is also made 10 
by the carboxyl group of an aspartate with a bound water molecule and a second aspartate to 
form the catalytic construct. (Seemuller et al., 1995b). 
Due to the nature of multiple catalytic activities and no similarity in DNA sequences 
or patterns of conservative residues to the known proteases, proteasome could not be 
assigned to any of these four families (Tamura et al., 1991). A classification was attempted 
on the basis of inhibitor studies (Orlowski et al., 1993; Dahlmann et al., 1992). The current 
conclusion is that a proteasome is not an aspartic or metal protease because of its insensitive 
to inhibitors of aspartic proteases and metal proteases (Dahlmann et al., 1992). Serine or 
Cysteine protease inhibitors have strong effects on proteasome, however, not in a typical 
manner. Recently, Seemull et al. (1995) reported that, in archaebacterium Thermoplasma 
acidophilum, N-terminal threonine of 20S proteasome is responsible for the nucleophilic 
attack. Fenteany et al. (1995) reported that in mammalian 20 S proteasome, the highly-
conserved amino terminal threonine residue of X/MB1 subunit active site is covalently 
modified by lactacystin - a potent inhibitor of proteasome. Thus we may assign "threonine 
protease" as the fifth category of proteases. 
Intracellular Proteases 
Studies of pathways of intracellular degradation have been aided by the availability 
of inhibitors and more recent techniques such as microinjection (Dice, 1990) and genetic 
manipulation. There are 4 major intracellular degradation system (based on Rivett, 1990), 
categorized by their localization, requirements for activation, and substrate, including 
1)lysosomal proteases (cathepsins), which are thought to be responsible for the degradation 
of long-lived proteins. 2)calcium-activated neutral proteases (calpains), which may be 11 
responsible for limited cleavage of regulatory protein and some myofibrillar proteins (Rivett, 
1990; Goll et al., 1989). 3) Multiple proteolytic complex or proteasome, which is considered 
to be responsible for error-eliminating activity and degradation of short-lived proteins and 
some long-lived proteins. It is also proposed to be involved in antigen presentation 
(Goldberg, 1991). This system may be further divided into two pathways (Peters et al., 
1994): ubiquitin, ATP-dependent and ubiquitin-independent systems. Activity of the 
proteasome is made up of several individual protease activities: trypsin-like, chymotrypsin­
like, branched-chain amino acid-preferring (BrAAP), small neutral amino acid preferring, 
peptidylglutamyl peptide bound hydrolyzing activities (Orlowski et al., 1993). 4) others, 
such as mitochondrial ATP-dependent protease, mitochondria processing protease (Cote et 
al., 1990). 
Lysosomal proteases 
Most early studies of proteases were limited to lysosomes: a well-defined organelle 
containing a number of highly active proteases usually called cathepsins, (e.g. Cathepsin  B, 
D, H, and L) Cathepsin B, D, and H are cysteine proteases whereas cathepsin D is an 
aspartic proteases. (Rivet, 1990). The general opinion is that lysosomes plays an important 
role in the degradation of endocytosed proteins and of "long-lived" intracellular proteins. 
Cathepsins have optimal enzymatic activities at pHs lower than 6 and  can hydrolyze 
endocytosed long-lived cellular proteins to amino acids, either through a non-selective 
pathway: macroautophagy and microautophagy, or via a selective pathway, the selective 
pathway has been detected under conditions of serum deprivation in cultured cells and 
starvation of animal tissue (Dice, 1990). The selective pathways were proposed to target 12 
cytosolic protein containing Lys-Phe-Glu-Arg-Gln (KFERQ, Dice,  1990) and membrane 
receptors tagged with ubiquitin (Hicke and Riezman, 1996). 
Calpains 
Calpain was first found in brain tissue (Guroff, 1964). Later, it was found to be 
responsible for the disappearance of Z-disk in muscle when muscle strips were incubated in 
a Ca2"-containing solution (Busch, 1972). It is a calcium-activated neutral cysteine 
endopeptidase (EC 3.4.22.17) ubiquitously distributed in all animal cells examined thus far. 
There are at least 6 distinct isozymes, differing in structure and distribution, including 
ubiquitous m-calpain, m-calpain, chick [Um calpain (Sorimachi et al., 1995; Wolfe et al, 
1989), and tissue-specific n-calpain-1(p94, skeletal specific, Sorimachi et al., 1989), n­
calpain-2 and 2'( both are stomach muscle specific; Sorimachi et al., 1993). A general 
structure of calpains consists of a large subunit  80 kDa with four domains: 1, II, III, and VI; 
and a small subunit  30 kDa, with two domains: VI' and V. 1), an exception is n-calpain-2 
which has only two domains in the large subunit, Domain I and II. 
Domain I is a "propeptide" domain; there is no sequence similarity in this domain to 
any known sequence in protein databases. Removal of the N-terminal 19 or 27 amino acids 
of m-calpain or fi-calpain dramatically lower the requirements of Ca  for catalytic 
activation suggesting a possible role for autolysis of calpain in its regulation (Suzuki et al., 
1981). Domain II, a cysteine protease domain, has similarity to other cysteine proteinases 
such as papain and cathepsins B, H and L, especially around their active-site cysteine 
histidine and asparagine residue (Takio et al., 1983; Sorimachi et al., 1995). The sequence of 
this domain between m- and pt-calpain is highly homologous compared with the other three 13 
domains (Suzuki et al., 1988). The sequence of Domain III is not homologous to any known 
proteinase sequences. This domain may be the phospholipids binding site of calpains (Saido 
et al., 1993) and may contain a calpastatin-binding region (Croall et al., 1994). Domain VI 
(in large subunit) and VI'(in small subunit) are calmodulin-like domains. Their sequences are 
similar to calmodulin and contain 4 EF-hand structures. This domain is possibly responsible 
for calcium-dependent regulation of calpain. Domain V, the N-terminal halfof small subunit, 
is a glycine-rich hydrophobic domain, which is believed to interact with membrane 
phospholipids (Suzuki et al., 1987; Imajoh et al., 1986). 
Direct study of the catalytic activity and substrates of calpains under normal 
physiological conditions have encountered many technical difficulties. Hence most of the 
features of calpains were determined in vitro. Calpain-catalyzed proteolysis is usuallynot 
digestive but limited: it does not hydrolyze protein to amino acids, but cuts the substrates to 
big pieces for modification purposes. An example is protein kinase C (PKC), which is 
digested at the hinge region between its regulatory and catalytic domains, producing  an 
active fragment (PKM; Savart et al., 1991).  Substrates of calpains can divided to 4 groups 
(based on Saido et al., 1994): 1) Structural proteins, including cytoskeletal proteins (e.g. 
fodrin, spectrin, talin, a-actinin and tubulin; Bilger et al., 1988) and muscle myofibrillar 
proteins (desmin, nebulin, troponin T, c-protein, titin, tropomyosin; Allen et al., 1986; Goll 
et al., 1991); 2) Membrane proteins, such as growth factor receptors, adhesion molecules 
(integrin, N-CAM; Takahashi, 1990; Wang et al., 1989); 3) Enzymes: protein kinase C, 
phosphatase, and phospholipases; and 4) others, such as cytokines, transcription factors 
(Fos, Jun; Hirai et al., 1991), and lens protein crystallin (Shearer et al., 1991). It was 
proposed that a cluster of hydrophilic sequences enriched in Pro, Glu, Asp, Ser and Thr (or 14 
PEST sequences) exists in most calpain substrates and are usually located near the cleavage 
sites (Wang et al., 1989). 
Factors which regulate calpain activities include Ca2- concentration, autolysis of 
calpain, binding to membrane phspholipids, dissociation of large and small subunits 
(Yoshizawa et al., 1995), concentration of the endogenous calpain inhibitor (calpastatin) 
and the presence of endogenous activators (Salamino et al., 1993). Obviously, Cat- is 
critical for calpain activation, the native calpains are completely inactive without  the 
presence of Ca2- (Suzuki et al., 1988). There is a mechanism proposed by Saido and 
coworkers (1994) for calpain activation involving binding to membrane and autolysing­
activation. However, in some cases, the activation of calpain does not require small subunit 
or autolysis of N-terminus (Crawford et al., 1993; Cong et al., 1993; Yoshizawa et al., 
1995). 
Calpastatin, an endogenous calpain-specific inhibitor, exists ubiquitously in various 
cells and is the only known proteinaceous inhibitor specific to calpain. The manner of 
inhibition is competitive, hence it must also bind to the active site on calpains (Kawasaki et 
al., 1989). It inhibits translocation of calpain to intracellular membranes, and also inhibit 
autolytic activation of calpain (Suzuki et al., 1988). The action of inhibition is also Ca2-­
dependent (Otsuka and Goll, 1987). It was reported that calpain binds to cell membranes 
through a site (regulatory site) other than the active site and that calpastatin inhibits the 
binding of calpain to cell membranes via a site (regulatory inhibition site) other than the 
inhibitory sequence (Kawasaki et al., 1993). 15 
Proteasome 
Proteasome, or multicatalytic proteinase complex (MCP), which is the major 
protease responsible for turnover of short-lived proteins, has attracted broad attention from 
different fields such as biochemistry, cell and structural biology, and immunology for two 
and one-half decades. At first, proteasome had been assigned at least 15 different names by 
different research fields. But, more recently, it has been determined as a single proteolytic 
range of cellular events (reviewed in Rechsteiner et al., 1993). 
The 20S proteasome is a cylindrical protein complex which is 11 x 17 nm in size, has 
a molecular weight 700 kDa, and a sedimentation coefficient of 20 S. In negatively-stained 
preparations, this complex appears as a ring-like image in an end-on view and as a four-
banded image in a side-on view. It is composed of approximately 12-15 different 
polypeptide subunits in the molecular weight range from 19 to 36 kDa. Immuno-localization 
studies showed that the particles are evenly distributed in the nucleus and cytoplasm of 
eukaryotic cells, without obvious associations with intracellular structures (Peters et al., 
1994). 20 S proteasome has been designated as multicatalytic proteinase (MCP), owing to 
its wide range of enzymatic activities. Now, up to 5 activities have been identified (Wilk et 
al., 1983; Vinitsky et al  1994) including a trypsin-like protease activity (TL), which cleaves 
the carboxyl side of basic amino acids; a chymotrypsin-like activity (ChT-L), which cleaves 
the carboxyl side of hydrophobic amino acid residue; a peptidylglutamyl hydrolyzing activity 
(PGPH), which cleaves the carboxyl side of acidic amino acid residue (Wilk et al., 1983); a 
branched-chain amino acid-preferring (BrAAP) activity; and a small-neutral amino acid-
preferring (SNAAP) activity (Vinitsky et al., 1994). Inhibitor studies indicated that these 
specificities are a consequence of different catalytic sites. The amount and activity of each 16 
catalytic component is different in various tissues. For example, chymotrypsin-like activity 
and the amount of subunit B02 were markedly lowered in lung than in bovine pituitary; the 
BrAAP component is predominantly latent in the pituitary but was highly activate in the lung 
and liver (Cardozo et al., 1995). 
The 26 S proteasome was first isolated from rabbit reticulocytes (Hugh et al., 1987) 
existing in both the cytoplasm and nucleus as an ATP- and ubiquitin-dependent  protease. It 
is assembled from the cylindrical 20 S particle, to which two large 19S cap-shaped 
complexes (which are also composed of many subunits), 20-30 kDa each, are bound end-on 
to both ends of 20 S proteasome, this results in a dumbbell-shaped complex (25 x 19 nm in 
size) with a molecular weight of approximately 2000 kDa (Peters et al., 1993). This huge 
protein complex is responsible for protein degradation in the ubiquitin pathway. The 
ubiquitin system is a non-lysosomal ATP-dependent proteolytic pathway in which covalent 
attachment of ubiquitin, a highly conserved and ubiquitous eukaryotic 76-residue 
polypeptide, is thought to mark proteins destined for degradation (Hershko and 
Ciechanover, 1992) by 26 S proteasome. The repetition of successive actions of three types 
of enzymes, ubiquitin-activating enzyme(E 1), ubiquitin-conjugating enzyme(E2), and 
ubiquitin-ligase(E3), result in the formation of large conjugates which are specifically 
recognized by the 26 S proteasome (Goldberg, 1991). The "19 S caps" of 26 S proteasome 
are thought to serve the functions for energy utilizing (ATPase), substrate specificity, re-use 
of ubiquitin (isopeptidase activity), and folding/unfolding substrate (Gottesman et al., 1992) 
to prepare the substrate for proteolysis by core proteases. In addition to the "19 S caps", 
other regulators of proteasome have been discovered. These include the inhibitors: 200 kDa 
inhibitor (Li et al., 1991) and 60 kDa inhibitor (Chu-Ping et al., 1992); and the activators: 17 
PA28 (Gray et al., 1994) and a 11 S regulator (Dubiel et al., 1992). The PA28 oligomer 
forms a stable complex with 20S proteasomes by capping both ends of the cylinder particle 
in a similar manner as "19 S caps". This result in a complex resembling the 26 S proteasome 
in its structure organization. 
Much evidence indicates that the 20S proteasome is the essential proteolytic site of 
26S proteasome. Various yeast mutants of the 20 S proteasome accumulate ubiquitin 
conjugates and do not degrade model substrates of the ubiquitin system (Heinemeyer et al., 
1991; Seufer et al., 1992). The proteolytic activities are thought to reside in the innermost 
part ( (3-subunit ring). 
Though clear specificities for protein substrates have not been revealed, through 
many indirect evidences, proteasome appears to play essential roles in maintaining normal 
cell functions, such as cell division, cell differentiation, and adaption to environment changes 
(Ghislain et al., 1993; Ichihara and Tanaka, 1995). This evidence includes: 1) yeast mutants 
defective in 26 S proteasome subunits exhibit cell-cycle arrest (Ghislain et al., 1993); 2) 
particularly highly expressed in various immature cells, such as cancerous, fetal and 
lymphoblastic cells (Ichihara et al., 1995); 3) Proteasome dramatically changes in 
intracellular localization during mitosis (Amsterdam et al., 1993), and 4) and proteasome is 
responsible for transcriptional regulator p53 degradation after being phosphorylated 
(Chowdary et al., 1994; Scheffner et al., 1993). Substitution of 13-subunits by 
immunological inducible subunits (LMP2 and LMP7) leads proteasome to generate antigens 
for major histocompatibility complex (MHC) class I - restricted antigen presentation 
(Michalek et al  ,  1993; Goldberg et al., 1992). Degradation or modification of other proteins 18 
have also been revealed. Examples include cell surface receptors and immunoglobulins 
(Ciechanover, 1994). 
Proteolytic activity of the 26 S proteasome is not absolutely ubiquitin- dependent. 
Murakami and coworkers (1992) showed that ornithine decarboxylase can be degraded by 
26S proteasome in the presence of antizyme in an ATP-dependent manner, through a 
ubiquitin-independent pathway. This pathway revealed another mechanism of selectivity in 
protein degradation (Murakami et al., 1992; Tokunaga et al., 1994). 
Protease Inhibitors 
Inhibitors of proteolytic enzymes are widely distributed in different tissues of 
animals, plants, and microorganisms. The regulation of proteolytic conversion of proteins 
and peptides in organisms is considered to be the main physiological function of these 
inhibitors. For intracellular proteinases, inhibitors are good tools for studying structure and 
functions of proteinases. The common laboratory-used inhibitors can be roughly divided 
into two categories: naturally-occurring and synthetic inhibitors. Example in the first 
category include: calpastatin (Toyohara et al., 1983), the endogenous proteinaceous 
inhibitor of calpain; chymostatin (Stein et al., 1987), a low molecular weight peptide-fatty 
acid compound of microbial origin that inhibits chymotrypsin and papain; cystatins (Freije 
et al., 1993), a group of natural cysteine-protease inhibitors, widely distributed both intra­
and extra-cellularly; lactacystin (Omura, 1991b), a hybrid of a 1-lactam and a N­
acetylcysteine connected by a thioester bond; leupeptin, an Actinomycete product, which is 
a tripeptide aldehyde analogue; and heat-shock protein 90 (HSP90) (Farrell et al., 1984), 
as endogenous proteasome inhibitor. Because of the poor cell membrane-permeability and 19 
high-cost of proteinaceous inhibitors, synthetic inhibitors, which are usually active site-
targeting peptides, are more often used for intracellular protease studies. Examples are 
leupeptin, calpeptin, calpain inhibitors I and II, which all belong to the peptide aldehyde 
family (Wang et al., 1994). 
The endogenous inhibitors are highly selective. For example, calpastatin inhibits only 
calpains but not other cysteine proteases (Kawasaki et al., 1993). HSP 90 blocks only 
benzyloxycarbonyl -Leu- Leu- 4- methylcoumaryl -7 -amide (ZLLL-MCA)-degrading ability in 
proteasome but not other catalytic activities in proteasome nor trypsin, chymotrypsin or m-
and id- calpains (Tsubuki et al., 1994). Generally speaking, synthetic inhibitors, as designed 
molecules, have better cell permeability than natural peptide inhibitors. In the other words, 
they are more easily internalized into cells than proteinaceous inhibitors. Unfortunately this 
class of compounds do not have satisfying selectivity for research or clinical purposes 
(Sasaki et al., 1990). For this reason, new compounds are continuously being developed and 
screened for their activities and specificities (Posner et al., 1995; Vinitsky et al., 1994). 
Calpain inhibitor II (CI-II) 
Calpain inhibitor-II (Acetyl-Leucinyl-Leucinyl-Methioninal)  was synthesized as a 
calpain-specific inhibitor (Figueiredo-Pereira et al., 1994a). But it also shows fairly strong 
inhibition of cathepsins L and B. In in vitro inhibitory activity tests on cysteine proteinases 
(Sasaki et al., 1990), the inhibitory constant (Ki) of inhibitors are shown as below: cathepsin 
H, greater then 10 uM; cathepsin B, 0.1 idM; cathepsin L, 6x104 µM; m-calpain, 0.23 p.M; 
and p-calpain, 0.12 idM. Which means the ability of CI-II to inhibit various proteases is in 
this order: cathepsin L > cathepsin B > [1-calpain > m-calpain > cathepsin H. However when 20 
the K, values were compared with Km values, the ratio KJ/Kin for m-calpain is 1.7 times 
smaller than that for cathepsin L, implying a higher relative specificity of inhibition of A­
calpain than of cathepsin L. The mode of calpain inhibitor II in inhibition of calpains is 
competitive and reversible. CI-II exerts different inhibitory effect on proteasomes' various 
activities. The IC50 against chymotrypsin-like, trypsin-like, and branched-chain amino acid-
preferring activities were 10, 25 and 12 MM, respectively. Under the same assay condition, 
0.5 - 1 AM CI-II inhibits calpain activity almost completely (Figueiredo-Pereira et al.,
 
1994a).
 
PD150606 
PD150606 is an oc-mercaptoacrylic acid derivative with an IC50 of 0.62 AM against 
A-calpain and 1.1 AM against m-calpain. The inhibition constant are 0.21 AM and 0.37 AM 
against A- and m-calpain, respectively, and 127.8 AM against cathepsin B. Apparently it is 
more selective towards substrate in in vitro test than CI-II. It appears to target the 
calcium-binding domains of calpain rather than the active site. The mode of inhibition to 
calpains is uncompetitive and reversible. Unlike transitional-state active site inhibitors, 
PD150606 did not inhibit calpain autolysis even at concentrations 100-fold its IC50 (Wang et 
al., 1995) 
Lactacystin 
Lactacystin was isolated from cultured broth of a Streptomyces strain. At first it was 
noticed to induce differentiation of neuroblastoma cells (Omura et al., 1991 a, b). It is also 
found to inhibit proliferation of other cell types (Fenteany et al., 1994). Later, surprisingly, 
through the identification of lactacystin-binding protein, it was revealed that lactacystin 21 
covalently binds to the N-terminal threonine triad of 20S proteasome subunit X/MB1 
(Fenteany et al., 1995: Seemuller et al., 1995a), which results in irreversible inhibition ofthe 
proteasomal chymotrypsin-like and trypsin-like activities. It also reversibly inhibits PGPH 
activity. Lactacystin did not show any detectable effects on cysteine proteases (calpains and 
cathepsin B), and serine proteases (chymotrypsin and trypsin; Fenteany et al., 1995a). 
Calpeptin and calpeptin analogue (CA) 
Calpeptin, a synthetic dipeptide aldehyde (benzyloxycarbonyl-Leu-norleucinal; 
ZLnL), is reported to be more cell permeable than calpain inhibitors I and II (Tsujinaka et 
al., 1990). It is a potent calpain inhibitor (Figueiredo-Pereira et al., 1994a) which can almost 
totally inhibit calpain activity at the concentration of 1 [IM. At a much higher concentration 
(100 pM) calpeptin inhibited the chymotrypsinlike activity by 55% and other proteasome 
activities by 10-20%. However, calpeptin also showed strong effect on cathepsin L (K, = 3.4 
nM, compared to m-calpain K,= 67 04 and to m-calpain Ki=62 MM; Sasaki et al., 1990). 
Calpeptin analogue, N-benzyloxycarbonyl-Leu-leu (ZLL), has the  same potency as 
calpeptin on calpain and proteasome activities (Figueiredo-Pereira et al., 1994a). 
ZIE(OtBu)AL-CHO (ZIE) 
N- benzyloxycarbonyl - Ile- Glu(O -t- butyl) Ala- leucinal, abbreviated as 
ZIE(OtBu)AL-CHO or ZIE, has a strong inhibitory effect (K1=0.25 MM) on proteasome 
when tested on degradation of succinyl-Leu-Leu-Val-Tyr-methylcoumarylamide. It 
specifically inhibits the chymotrypsin-like activity of proteasome. After being treated with 
ZIE, activities of trypsin-like and peptidylglutamyl peptide hydrolyzing activities, at an 
inhibitor concentration of 65 MM, were suppressed by 14% and 9%, respectively. It is also 22 
an inhibitor of calpain (IC50 = 4 p.M) In Western-blots, it showed strong accumulation of 
ubiquitin-protein conjugates in neuronal cell line cytosol (Figueiredo-Pereira et al., 1994a). 
Myofibrillar Protein Turnover 
Normal intracellular protein turnover is physiologically important for cells to change 
the protein level during cell development processes, in response to external signals, and to 
remove damaged and mis-assembled proteins. The most prominent example is cyclin  the 
regulatory protein for cell cycle, which is degraded at the start of chromosome separation 
(Sherwood et al  1993). The other importance of intracellular protein turnover is 
mobilization of body protein in response to malnutrition and diseases such as cancer 
cachexia (Tessitore et al., 1993), to degrade the "luxury" proteins in order to use their amino 
acids to build-up proteins more essential for survival. Myofibrillar proteins, as the most 
abundant protein pool of the whole body, are usually mobilized in these cases (reviewed in 
Sugden and Fuller, 1991). The half-lives of muscle proteins (Kayali et al., 1987 ; Wolitsky et 
al., 1984) range from 2 to 20 days, except myosin (30 days) and actin (more than 50 days). 
Much available evidence indicates that myofibrils grow and turnover by adding and 
removing filaments from their surfaces (Morkin, 1970). Approximately 5  10% of total 
myofibrillar protein is in the form of easily released myofilaments that are rapidly labeled and 
seem to be intermediates in metabolic turnover of myofibrils (Van der Westhuyzen et al., 
1981). 
Lysosomal cathepsins 
Among lysosomal proteases, cathepsin B, D, H (cysteine proteases) and L (aspartyl 
protease) have high activities in skeletal muscle cells. In In vitro experiments showed that 23 
cathepsin L degrades myosin heavy chain, actin, -actinin, troponin T, and troponin I 
(Matsukura et al., 1981). However this is very unlikely to occur in healthy cells because 
cathepsins are not active at cytosol where pH values higher than 6 (Okitani et al., 1981; 
Matsukura et al., 1981; Lowell et al., 1986). Products of disassembled myofilament 
fragments and myofibrillar protein have been detected in a few lysosomes(Libelius et al., 
1979). A recent report of late-onset distal myopathy (Kumamoto et al., 1994) showed some 
positive immunostaining for myosin, alpha-actinin and actin within the rimmed vacuoles. It 
is reported that the inhibition of protein breakdown by IGF-I may be mediated by 
autocatalytic inactivation of lysosomal cathepsins B and L (Tsujinaka et al., 1995). 
Cathepsin activities were found to increase under some abnormal conditions, such as fasting 
(Belkhou et al., 1994) cancer cachexia (Temparis et al., 1994), and malnutrition (Tessitore 
et al., 1993). However their activities are not directly related to myofibrillar protein 
turnover. In dexamethasone-treated L8 myotubes, cathepsin B, D and calpain mRNA 
increased significantly (Hong and Forsberg, 1995). Cathepsin B is able to degrade 
myofibrillar protein in vitro, such as myosin heavy chain, actin and troponin T with an 
optimal rate at around pH 5. Cathepsin B causes the fragmentation of myofibrils and 
disturbance of the lateral arrangement of myofibrils. It partly disintegrated the Z- and the 
M-lines, and induces disordering of the arrangement of filaments in the I-band (Matsuishi et 
al., 1992). 
Calpains 
It was first proposed by Dayton and coworkers (1976a, b) that calpain is responsible 
for initiation of metabolic myofibrillar protein turnover. Much evidence suggests that the 24 
calpain system is crucial to initiating myofibrillar protein degradation (reviewed by Goll et 
al., 1992), evidence include: 1) Increase of intracellular Cat- concentration changes and 
always corresponds to the increase in muscle total protein degradation (Sugden, 1980; 
Lewis et al., 1982; Zeman et al., 1985). Calpain is the only known Cat -- dependent protease 
active in normal cytosolic condition. 2) Treatment with leupeptin reduced the size of the 
easily-releasable myofilament fraction (van der Westhuyzen et al ,  1981). Treatment of 
muscle cells with a potent inhibitor of calpains (leupeptin and chymostatin) delays muscle 
cell degeneration or decrease the rate of muscle protein degradation in dystrophic or 
denervated muscle or muscles incubated in vitro (Libby and Goldberg, 1980; Stracher et al 
1979). Calpain Inhibitor II (N-acetyl-leu-leu-methioninal), a more selective calpain 
inhibitor, shows strong ability to stabilize the myofibrillar protein fraction of L8 myotubes 
(Ou, 1995). 3) Immunolocalization studies indicate that the calpains and their endogenous 
inhibitor calpastatin are located inside muscle cells on myofibrils with their highest 
concentration at the Z-disk (Kumamoto et al., 1992), which is the structure removed by 
calpains (Busch et al., 1972). The Z-disk alteration is one of the most consistent structural 
changes seen in rapidly atrophying muscle afflicted with muscular dystrophy, denervation, 
and in various muscular pathologies (Otsuke et al., 1985; Goll et al ,  1989). Denervation and 
fasting will increase concentrations of calpains and calpastatin but not their location 
(Kumamoto et al  1992). In addition, the calpains seem to be responsible for degradation of 
costameres and N2 lines (Taylor et al., 1995a) and, among the known proteases calpains are 
unique in that they do not degrade nondenatured myosin and actin (Dayton et al., 1976), but 
they will release a-actinin without degrading it (Lane et al., 1977; Goll, 1991). 25 
Proteasome 
The multicatalytic, widely distributed, and highly conserved  nature of proteasome 
indicates that this protease is important to general protein degradation and reutilization 
(Rock et al., 1994). Under abnormal physiological conditions, it was observed that 
proteasome is involved in the process of muscle protein turnover. Examples include 
denervation and starvation atrophy (Medina et al., 1995); acidosis, which evokes  a 
glucocorticoid-dependent catabolic response by stimulating ATP-dependent, ubiquitin­
dependent proteolytic pathway (England et al., 1995); tumor-bearing muscle wasting in 
cancer cachexia (Temparis et al., 1994). Tumor necrosis factor (TNF) enhances the 
ubiquitination of muscle proteins (Llovera, 1994). Recently, it is reported that 20S 
proteasome can degrade myosin heavy chain, a-actin, and desmin in incubated glycerinated 
muscle fibers, this is followed by degradation of a-actinin, troponin T, and tropomyosin. 
The changes in ultrastructure were slow and the pattern of protein degradation is quite 
different from which observed in muscular disorders and postmortem changes (Taylor et al., 
1995b). In lobster muscle, heat activated BrAAP activity of proteasome may be responsible 
for the initiation of myofibrillar protein degradation (Mykles, 1993; Mykles et al., 1995). 
Contrary remains regarding the true function of the various proteolytic system in 
skeletal muscle. In the past two years, several new, relatively specific inhibitors have become 
available. Our goal, therefore, was to use these inhibitors to more accurrately pinpoint the 
function of the proteasome and calpain in muscle cells. MATERIALS AND METHODS 
Materials 
The L8 rat myoblast cell line was obtained from American Type Culture Collection, 
(Rockville, ME). Dulbecco's modified Eagle's medium (DMEM), penicillin, streptomycin 
and trypsin were from GIBCO (Grand Island, NY). Fetal bovine serum (FBS) and horse 
serum (HS) were from Hyclone (Logan, UT). Cell culture dishes and plates were from 
Corning (Corning, NY). Calpain inhibitor II (N-Acetyl-Leu-Leu-Methioninal) and PMSF 
were from Boehringer Mannheim (Indianapolis, IN). PD150606 and PD145305 were gifts 
from Dr. Kevin K. W. Wang (Warner-Lambert Company, Ann Arbor, MI). Lactacystin was 
provided by Dr. S. Omura (Kitasato Inst., Tokyo, Japan). Proteasome inhibitors 
ZIE(OtBu)AL-CHO ( ZIE, N- benzyloxycarbonyl - Ile- GIu(O -t- butyl) Ala - leucinal) and 
Calpeptin analog (CA, N-benzyloxycarbonyl-leucine-leucinal, ZLL) were gifts of Dr. 
Sherwin Wilk (Mt. Sinai Medical Center, NY). 3H-tyrosine(3,5-'H) was from New England 
Nuclear (Boston MA). EcoLum liquid scintillation cocktail solution and 35S­
methionine/cystine were from ICN (Costa Mesa, CA). Cytosine -D-arabinofuranoside 
(Ara-C), ubiquitin antibody, bovine serum albumin (BSA), dithiothreitol(DTT), EDTA, 
glycine, 13-mercaptoethanol ((3-ME), sodium dodecyl sulfate(SDS), Triton X-100, Tween­
20, trichloroacetic acid (TCA), benzamidine-HC1, leupeptin and anti-ubiquitin antiserum 
(U5379) were from Sigma Chemical Co. (St. Louis, MO). Horseradish peroxidase (HRP)­
conjugated goat anti-rabbit IgG, molecular weight marker, polyacrylamide/bis solution, 
TEMED, and ammonium persulfate were from Bio-Rad (Richmond, CA). The ECL 
Western blotting detection system was from Amersham (Arlington Heights, IL). 17 
Nitrocellulose membrane was from Schleicher and Schuell (Keene, NH). Autoradiography 
film REFLECTIONTm was from NEN (Boston, MA) 
Cell Culture 
L8 rat myoblasts were grown in DMEM with 10% FBS, 100 units of penicillin/ml, 
100 mg streptomycin/ml and 44 mM sodium bicarbonate in a humidified atmosphere of 5% 
CO2 and 95% air at 37 °C. The medium was changed every two days. After cells reached 
100% confluence, the medium was replaced with DMEM containing 2% HS to induce 
differentiation. Microscopic examination was used to monitor cell differentiation. AraC (10 
MM) was added to prevent further proliferation, three to five days of culture in 2% HS were 
required to generate a terminally-differentiated population of myotubes. Inhibitors (CI-II, 
PD150606, lactacystin, ZIE, and CA) were added directly to culture media. 
Inhibitor Treatments 
After myoblasts had matured into myotubes, they were treated with 1 p.Ci/m1 of 
3H-tyrosine in differentiation media (DMEM/2% HS) for 36 hours. Cells then were washed 
with DMEM twice, supplemented with differentiation media containing 2 mM of non­
radioactive tyrosine and inhibitors, and incubated under the same environmental condition 
for 24 hours. Concentrations of inhibitors used in this experiment are listed as below. 
PD150606, (0.1, 1, 10 and 100 MM), was dissolved in 99.9% DMSO. Calpain-Inhibitor-II, 
(75 MM), was dissolved in 99.9% DMSO. Lactacystin, (0.01, 0.1, 1, and 10 [EM), was 
dissolved in pure water. Calpeptin analogue, (0.01, 0.1, 1, and 10 MM), was dissolved in 
pure water, and 25 µM ZIE(OtBu)AL-CHO, (0.01, 0.1, 1, 10 and 25 MM), was dissolved in 
DMSO. In all treatments, solvent volume did not exceed 0.002% of media volume. 28 
Experiments were repeated at least three times and each treatment had three replicates. A 
blank control (without any inhibitor) and a positive control (calpain inhibitor IItreatment, 75 
I_IM) were included in every experiment. 
Total Protein Degradation and Index of Cvtotoxicity 
Myotubes were prelabeled for 24 hr by incubation in DMEM with 3H-tyrosine. 
Following this, radioactive medium was removed, cells were washed with differentiation 
medium and culture medium was replaced with differentiation medium containing 2 mM 
non-radioactive tyrosine. To this medium, inhibitors were also added. After 24 hours of 
incubation with treatments (or without treatment for blank control), cell culture medium 
was transferred to a microcentrifuge tube and TCA was added to a final concentration of 
10 %(wlv) to precipitate proteins and peptides. After incubating samples at 4 °C for 1 hour, 
samples were centrifuged for 10 minutes at 14,000g, supernatants were collected. This is the 
portion contains free 3H-tyrosine and represents the extent of intracellular protein 
degradation. The rate of total protein degradation was determined by radioactivity 
associated with this fraction. Pellet which remained at the bottom of microcentrifuge tube 
was dissolved in 0.5N NaOH/0.1% Triton X-100. This portion is considered as an index of 
cytotoxicity. Both supernatant and dissolved pellet were added to liquid scintillation cocktail 
counting solution and their radioactivities were determined in a Beckman Model LS6000 SE 
scintillation counter. 
Separation of Non-myofibrillar Protein-rich and Myofibrillar Protein-rich Fractions 
Separation of non-myofibrillar and myofibrillar fractions was based on the method of 
Wolitsky et al. (1984). After culture media was aspirated, cell monolayers were washed 3­29 
times with ice-cold PBS (pH 7.4) and then homogenate buffer containing 20 mM Tris-HC1 
(pH 7.0), 5 mM EDTA, 1 mM PMSF, 0.01% leupeptin, 50 mM 13-ME, 1mM benzamide-
HCI, and 0.35 M sucrose was added. Cells were scraped with a rubber policeman and 
transferred to a Dounce homogenizer, then homogenized with 15 strokes of a tight-fitting 
pestle. The homogenate was centrifuged at 1000g for 5 min at 4 °C. The supernatant was 
referred to as the non-myofibrillar protein-rich fraction. The pellet, which contained the 
myofibrillar protein-rich fraction, was dissolved in 0.5 N Na0H/0 1% Triton X-100 for 
counting of 'H radioactivity, or washed with homogenate buffer twice for SDS­
polyacrylamide gel electrophoresis. Both fractions were added to LSC counting solution 
and radioactivities was determined by liquid scintillation counting. If the pellet was to be run 
on a polyacrylamide gel electrophoresis (for 35S-methionine autoradiography experiments), 
it was dissolved in sample buffer which contained 2.3% SDS and 62.5 mM Tris buffer 
(pH6.8) and 5% P-mercaptoethanol in 10% glycerol. Samples for ubiquitin antibody 
Western blotting were processed as whole homogenates without separation of myofibrillar 
and non-myofibrillar-rich fraction. 
Polyacrylamide Gel Electrophoresis 
Myofibrillar protein-rich fractions were dissolved in sample buffer then 
electrophoresized (Laemmli, 1970) on 7.5% to 15% polyacrylamide gradient gels for 
autoradiography of35S-methionine-labeled myofibrillar proteins. A 7.5% gel was used for 
routine analysis of ubiquitin-protein conjugates. 30 
Autoradiography 
When L8 cells reached 90% myotube, cells were cultured in starvation media 
(methionine/cystine-free DMEM with 2% HS) in a CO2 incubator for 15 minutes, then 
changed to labeling media (35S-methionine/cysteine 20 Ki/m1 in Met/Cys-free DMEM with 
2% HS) and incubated for an additional 8 hours. Cells were then washed with 37 °C chase 
media (DMEM with 2% HS, 1 mM methionine and 1 mM cystine), followed by incubation 
in chase media with designated inhibitors for 24 hours. Myofibrillar proteins were obtained 
according to the methods described previously. 100 mg of protein from each sample were 
loaded for electrophoresis, followed by heat-drying of the gel under vacuum for 1 hour at 80 
°C, then exposed to autoradiography film for 3 hours. 
Western Blot Detection of Ubiquitinated Proteins 
Cells were cultured as terminally-differentiated myotubes as previous mentioned. 
Sublethal doses of inhibitor were added to cell cultures (CI-II 75 MM, CA 25 MM, ZlE 1 
MM, and Lactacystin 5 p.M) and incubated for 6 hours. Monolayer cells were collected and 
homogenized as described previously. Samples of whole homogenate (100 p.g of protein) 
from each treatment were separated on a 7.5% polyacrylamide gel. After electrophoresis, 
proteins were transferred to nitrocellulose membranes (0.45 p.M) at 4 C overnight in 30 
volts by the method of Towbin et al. (1979) in transfer buffer containing 20% methanol, 25 
mM Tris-HC1 and 192 mM glycine. Membranes were then incubated in blocking solution: 
5% non-fat skim milk in TTBS (50 mM Tris-HC1, pH 7.5, 0.5 M NaC1, 0.05% Tween-20) 
for 1 hour at room temperature (RT). Following this incubation, the membrane was washed 
four times with TBS (Tris-buffered saline: 50 mM Tris-HC1, pH 7.5, and 0.5 M NaCl) at RT. 31 
Rabbit anti-ubiquitin antiserum were utilized for the first antibody incubation, after which 
the membrane was washed 3 time with TTBS. Horseradish conjugated goat anti-rabbit IgG 
was used for the secondary antibody incubation, washed 3 times with TTB S. Finally, 
ubiquitinated protein were detected by Amersham's ECL detection system. 
Densitometer 
Western blot results were scanned by Personal Densitometer SI (Molecular 
Dynamics) and analyzed by using ImageQuaNTTm software (Molecular Dynamics). 
Calculation Formula 
The effect of inhibitors on different fractions protein pools were expressed as 
percent of control, which were calculated by their least significant means of radioactivity 
counted. Effect of inhibitors on total protein degradation were expressed as cpm related to 
media (Figures 1) and as % inhibition of protein degradation using the following equation. 
cpm (treated group)  cpm (blank control) Effect (% of control) =  x 100% 
cpm (blank control) 
Effect of inhibitors on myofibrillar and non-myofibrillar protein degradation were 
expressed as cpm remaining in these fractions (Figures 3 and 5, respectively) and as 
stabilization of the two pools (Figure 4) using the same formula above. Stabilization is 
caused by a reduction in degradation. 32 
Statistical Analysis 
For experiments on effects of inhibitors on different cell fractions, effect of each 
inhibitor were repeated at least three times with three replicates for each treatment. Data 
were analyzed with multiple way ANOVA with Fisher's least-significant difference (LSD) 
method for comparing groups (Statgraph version 7.0). Values are presented as means ± SE. 
P value smaller than 0.05 is considered as statistical difference. 33 
RESULTS 
For every experiment, a blank control and a positive control group were always 
included. A blank control consisted of myotubes incubated in DMEM supplemented with 
2% HS but containing no inhibitor. A positive-control consisted of the addition of 75 1AM 
calpain inhibitor II (CI-II) to the above mixture. The rationale for using the positive control 
was that CI-II in previous studies (Ou, 1994) has shown to consistently reduce L8 muscle 
cell total protein degradation and increase myofibrillar protein accretion. 
In this study CI-II consistently reduced total protein degradation (TPD) and 
increased radioactivities remained in myofibrillar protein fraction. It reduced TPD by 32.1% 
to 52.2% (compared to blank control, % of control) and stabilized myofibrillar proteins by 
20.5% to 31.7% (compared to blank control) (p<.001). 
Data are presented as counts per minute (cpm) or as % of control, see "calculation 
formula" of "materials and methods" for details. 
Effects of inhibitors on total protein degradation (TPD) 
Effects of different proteinase inhibitors on total protein degradation in L8 cells are 
shown in Figure 1 as cpm released into culture media from the cultures and Table 1 as % of 
control. 
At all concentrations tested, the calpain-specific inhibitor  PD150606, did not 
decrease total protein degradation (TPD); while all other inhibitors all reduced TPD in a 
dose-response manner. The highest concentration of inhibitors always resulted in the 
greatest reduction in TPD. Higher concentration than those reported here always caused 
extensive cell detachment from the bottom of culture dish. 34 
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Figure 1. Effects of various inhibitors at different doses on total protein degradation. Effects 
of CI-II are shown in the last column as a positive control. After incubating inhibitors with
3H-tyrosine-labeled 
myotubes, culture media was collected, TCA precipitated, and 
centrifuged to obtain the supernatant which contains only free amino acids. This represents 
the end-product of total intracellular protein degradation (TPD). Supernatant radioactivity 
was determined by liquid scintillation counting. Units are given as cpm (counts per 
minute)/plate. X axis: doses used in this study. Y axis: Radioactivity associated with free 
amino acids in culture media. Inhibitors used in this study were: PD150606, calpeptin 
analogue, lactacystin, and ZIE. Different alphabetic letters (a, b, c, and d) signify statistical 
differences (p<.05). Table 1. Effects of inhibitors on total protein degradation (TPD) 
Values in this table shows the reduction of total protein degradation (effect) when compared to blank control group. Calculation 
formula: effect = cpm t {(of treatment group)  cpm (of control group) )/cpm (of control group)}%, presented as "TPD (% of 
control)" 
Symbols and abbreviations:  --- : not tested;  SE : standard error of least square mean expressed as % of control; CA: calpeptin 
analogue; LACT: lactacystin; ZIE: N- benzyloxycarbonyl Ile- Glu(O -t- butyl)- Ala - leucinal; values with bold numbers are statistically 
different from blank control group. 
*: inhibitors concentrations in this column is 30 11M for PD150606, and 25 1AM for others. 
**: CI-II (75 1AM) is the positive control in each inhibitor group. 
reduction of TPD, % of control INHIBITOR 
0.01  0.1  1  10  25/30*  100  SE  CI-II** 
PD150606  +0.58  -1.4  +0.77  +1.26  +0.02  ±1.02  -52.2 
CA  -2.36  -6.99  -22.72  -44.44  ±2.38  -36.36 
LACT	  -11.29  -12.11  -16.28  -26.22  ±1.53  -32 
ZIE  -10.74  -25.63  -44.43  -51.64  -52.52  ±4.07  -39.87 36 
Comparing their maximal effects on TPD (Fig. 2), ZIE exerted the greatest effect on 
total protein degradation (52%), followed by CA (44%) and LACT (26%). In  all 
experiments, CI-II caused approximate an 40% reduction in total protein degradation. 
0 
100%  4111  MEMMO111I 
0 
0 
50% 
0% 
CO  CI-II  CA  LACT  ZIE  PD 
Figure 2. Inhibitors' maxmum effects on total protein degradation. ZIE and CI-II showed 
the most prominent effects. PD150606 has no effect. X axis: various inhibitors; Y axis: 
effect on inhibition of TPD calculated by the formula shown in "materials and methods" 
Effect of inhibitors on myofibrillar protein and non-myofibrillar protein fractions 
Effects of protease inhibitors on myofibrillar-protein degradation was determined by 
recovering the myofibrillar protein fraction following exposure of 3H- tyrosine labeled 
myotubes to inhibitors for 24 hours, and then assessing the radioactivity associated with this 
pool. Results are shown in Table 2 (as percent reduction of myofibrillar protein degradation 
compared to control) and in Figures 3 (as cpm remaining in the myofibrillar fraction; 
myofibrillar protein stability). The maximal effects of inhibitors on myofibrillar protein 
fraction are shown in Figure 4. Table 2. Effects of inhibitors on myofibrillar protein degradation 
Reduction of degradation of myofibrillar protein fraction is expressed as the % stabilization of this pool (effect), calculation formula: 
effect = {cpm (treatment group) cpm (blank control))/ cpm (blank control))%, presented as " % stabilization of myofibrillar 
protein pool".
 
Symbols and abbreviations: --- : not tested; SE : standard error of least square mean expressed as % of control; CA: calpeptin
 
analogue; LACT: lactacystin;  N-benzyloxycarbonyl-Ile-Glu(0-t-butyl) -Ala-leucinal; values with bold  numbers were statistically 
different from blank control group (p< .05). 
**: CI-II (p.M) is the positive control included in each group of inhibitors. 
stabilization of myofibrillar protein fraction, % of control INHIBITOR 
0.1 0.01  1  10  25  SE  CI-11" 
CA  -2.32  +16.73  +4.23  -0.05  ±3.87  +20.4 
LACT  -7.62  -3.49  -4.96  +12.55  ±5.45  +20.5 
ZIE  +1.85  +6.61  +17.31  +26.96  +26.73  ±7.7  +31.6 38 
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Figure 3. Effects of various inhibitors on 
myofibrillar protein stability. After 
washing with ice-cold PBS, monolayered­
cells were scraped, homogenized, and 
centrifuged at 1000g for 10 min. The 
myofibrillar protein-rich fraction was 
pelleted. Pellets were dissolved in alkaline 
detergent and added into LSC cocktail for 
liquid scintillation counting. X axis: 
various concentration of inhibitor; Y axis: 
radioactivities associated with myofibrillar 
fractions. Inhibitors analysed in this study 
were: calpeptin analog, lactacystin, and 
ZIE. 
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Figure 4. Inhibitors' maximum effect on stabilization of myofibrillar proteins. CI-II and ZIE 
were equivalent in their abilities to stabilize myofibrillar proteins. Values are given as 
percent stabilization of the myofibrillar pool. compared to control. X axis: various inhibitors, 
Y axis: Stability is expressed as a % of control, the point cross X axis is 100%. Calculated as 
indicated in "materials and methods". An increase in this fraction implies a stronger 
inhibition of degradation of this fraction. 39 
A larger increase in radioactivity associated with myofibrillar proteins indicates a 
stronger inhibition of myofibrillar protein degradation (Table 2). ZIE, again, exerted the 
greatest inhibition on myofibrillar protein degradation by 26.73%. Calpeptin analogue (1 
pM) also stabilized myofibrillar proteins by 16.73% but had no effect on myofibrillar 
degradation at higher concentrations. Lactacystin did not significantly affect degradation of 
this pool (P>.05). CI-II (75pM) also significantly reduced degradation of the myofibrillar 
pool (Fig. 3 and 4 and Table 2) strongly (20.4% - 31.6% of reduction). 
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Figure 5. Effects of various inhibitors on  " 10000 -­
non-myofibrillar protein stability. (see Fig.3  E 
legend for detail). 
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Among all inhibitors and all doses tested, the radioactivities associated with non­
myofibrillar protein pools (Fig. 5) were not different from blank control group, except 
lactacystin at 10 pM. However the decrease in radioactivity associated with this pool of 
proteins was attributed to cytotoxicity and cell death. 40 
Cytotoxicity 
Visible cytotoxicity (as assessed under the microscope) of inhibitor treatments 
appeared only at high concentrations of treatments. For example, 25 [tM of calpeptin 
analogue, 10 [iNI of lactacystin, and 10 p.M of ZIE(OtBu)AL-CHO (ZIE) caused cells to 
look unusual. Doses higher than these resulted in cell detachment. CI-II-treated cultures did 
not display visible cytotoxicity in all experiments. 
Since some inhibitors at high concentrations appeared to be cytotoxic by visual 
analysis under microscope, we decided to look more closely at this issue since cytotoxicity 
could influence our calculation of inhibitors' effects. Our assumption was that the TCA­
precipitable protein in culture medium would contain secreted proteins and detached cells. 
Therefore, radioactivity associated with this fraction can be considered as cytotoxicity. 
After incubation of labeled myotubes with or without inhibitor, culture media was 
collected. The proteins were then precipitated with TCA and recovered by centrifugation. 
The pellet was dissolved by alkaline detergent (Na0H/SDS), and added to LSC cocktail for 
liquid scintillation counting. 
The result of cytotoxicity index showed that calpeptin analog and ZIE at all 
concentrations, except 1µM of CA, caused an approximate 30% to 40% increase in 
radioactivities associated with TCA-insoluble protein fractions compared with blank 
control. The effect caused by CA was equivalent to that caused by CI-II and roughly 
equivalent to ZIE (Fig. 6). The cytotoxicity index of lactacystin was not assessed, but the 
visible cytotoxicity was detectable at concentrations 10 [tM and above. 41 
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Figure 6. Index of cytotoxicity. Including: calpeptin analog, and ZIE(OtBu)AL -CHO). The 
method was described in Fig. 1. The medium was sampled and TCA precipitated, 
centrifuged, and supernatant asperated. The pellet was dissolved in alkaline detergent 
followed by liquid scintillation counting as described previously. X axis: various 
concentrations of inhibitors; Y axis: radioactivity associated with medium TCA-insoluble 
fraction. 
The final and major goal of the research was to identify the mechanisms accounting 
for myofibrillar protein degradation in cultured myotubes. Our earlier work had indicated 
that calpains played the key role in this process: however, in this study both inhibitors of 
calpain (by CI-II and CA) and of the proteasome (ZIE) reduced myofibrillar degradation. 
These data caused us to believe that both calpains and the proteasome may degrade 
myofibrillar proteins. To more thoroughly evaluate the function of various proteases in 
myofibrillar protein degradation, we measured the effects of the inhibitors on ubiquitination 
of muscle proteins. Our rationale was that inhibitors which truly function by inhibition of the 
proteasome should cause accumulation of ubiquitinated proteins. 42 
To complete the 
study, we assayed ubiquitin-
CO  CI CA  IA  ZIE protein complexes in 
myotubes following their 
treatment with various 
inhibitors via Western blot 
analysis ( Fig. 7). CI-II had 
no effect (p>.05) on 
ubiquitin-complex 
accumulation. Conversely, 
CA (25p.M), lactacystin 
(5pM), and ZIE (1µM) 
increased poly-Ub-protein 
Figure 7. Ubiquitin Western blot. Myotubes incubated 6 
hours in the absence or presence of inhibitors were complex accumulation 
homogenized. 100 ps of whole homogenate samples 
were electrophorisized on a 7.5% SDS-PAGE gel. (p<.05) compared to blank 
Followed by detection of Ub-protein conjugates. CO: 
blank control; CI: 75p.M CI-II; CA: 25 tM calpeptin control. These data suggested 
analog; LA: 5µM lactacystin; ZIE: 1 pM ZIE. 
that the latter three inhibitors 
(CA, LACT and ZIE) exert their effects, at least in part, via the proteasome. The lack of an 
effect of CI-II on poly-Ub-protein complexes indicates that its effects are not mediated via 
control of the proteasome, but more likely, via the calpains. 
An attempt to use an autoradiography method to identify the proteins being 
stabilized by these protease inhibitors was tried (Fig. 8). Myotubes were labeled with 35S­
methionine, after which decay of radioactivities in the presence or absence of inhibitors for 43 
24 hours was permitted. Myofibrillar proteins were recovered, electrophoresized on an 
SDS-PAGE gel and exposed to autoradiography film. Following exposure we examined the 
film hoping to identify specific proteins in the myofibrillar pool which were stabilized by 
inhibitors. Unfortunately, stabilization of proteins was not detectable with this method. 
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Figure 8. 35S-Methionine autoradiography. Myotubes labeled with 35S-Methionine were 
incubated in the presence or absence of inhibitors for 24 hours. Myofibrillar proteins were 
recovered and electrophoresized on a 7.5%-15% gradient SDS-PAGE gel. Gel then was 
dried and exposed to an autoradiography film. Samples are CO: blank control; LA: 5 p,M 
lactacystin; Z: 0.1 tM and 1p,M of ZIE; CA: 10 plq and 25 ;AM of calpeptin analog. 44 
DISCUSSION
 
L8 Myoblasts 
The L8 myoblast cell line was the major material used to study muscle biology in this 
study. We found that it was important to bring the cells to a fully-differentiated state to get 
repeatable results. Approximately one-year of effort was expended in learning how to 
successfully culture this cell line as myotubes. Factors related to differentiation of this 
muscle cell line included attachment to the matrix, proper lot of serum, proper heat-
inactivation of serum, more than 90% confluency of myoblasts in the culture dish, and the 
cells. The last requirement is apparently more crucial than others, and all other factors are 
almost of the same importance for obtaining good differentiation. The L8 cell line, through 
generations, tends to lose its ability to fuse (Richler and Yaffe, 1971; Yaffe and Saxel, 
1977). Hence, it is recommended to use early passages and the line should be recloned 
periodically to select for progeny that exhibit fusion (ATCC, 1992). Sera used in this study, 
including fetal bovine serum for proliferation and horse serum for differentiation, were 
tested and selected from several different lots to ensure that they were suitable for the cells 
we used in our laboratory. Before being applied to culture media, sera were heat inactivated 
at 56 °C for 30 min. Improper inactivation of sera may result in poor proliferation, cell 
detachment and poor differentiation. Confluency of myoblasts affects quality of 
differentiation, especially for cells after many passages. Usually it is necessary to grow cells 
to 100% confluency before change to differentiation media. It is already known that fusion 
of myoblast is cooperative: the fused cells will secrete growth factors which stimulate other 
cells to fuse (Alberts et al., 1994). 45 
Function of proteolytic systems 
The goal of this study was to investigate which protease plays a crucial role in 
myofibrillar turnover under normal physiological conditions. The current model suggests 
that calpains initiate turnover of the myofibrillar proteins by nicking myofibrils near the Z-
disk, resulting in loosening of thin and thick filaments which are then released to the 
sarcoplasm intact. The further breakdown of myofibrillar fragments is proposed to be 
mediated by other proteases such as lysosomal cathepsins and the proteasome (Goll et al., 
1989). Despite this model, other researchers strongly believe that the proteasome plays the 
more important role in myofibrillar protein degradation. In this study, various inhibitors 
targeting different proteases were employed to distinguish the role of various proteases in 
myofibrillar protein turnover. 
Effects of different inhibitors on different fractions of myotubes have been assessed 
in this study. Total protein degradation (TPD) was determined by the release of 3H-tyrosine 
into culture media. This is assumed to reflect the amount of total end-product of cellular 
protein turnover. All inhibitors tested here, except PD150606, caused a dose responsive 
reduction in TPD (Figure 1). PD150606 has been tested in intact human leukemic Molt-4 
cells and demonstrated stabilization of spectrin, a calpain-specific substrate (Wang et al., 
1995). It had no effect (P>.05) on TPD of L8 myotubes. It was not toxic to cells (not even 
at 100 piM, a concentration 10- to 20- fold higher than used in Molt-4 cells to reduce 
spectrin breakdown). From these results we concluded that this compound may not well 
cell-permeable in L8 myotubes or may be easily degraded intracellularly. PD150606 has not 
been extensively tested as a calpain inhibitor in mammalian cells. Although we had hoped it 
would help us define functions of proteases in muscle cells. Its inability to affect total protein 46 
degradation indicated that it was of little value in muscle cells. Hence, we discontinued its 
use in further experiments. 
Calpeptin analog (N-benzyloxycarbonyl-leu-norleucinal, or ZLL, abbreviated  as 
CA) reduced total protein degradation by 7%, 23%, and 44% at 1, 10, and 25 OA 
respectively. This effect was not directed so much at the myofibrillar protein pool because 
myofibrillar protein degradation was reduced only 17% by 1 jiM of this inhibitor. Its action 
on TPD might have resulted primarily from the ability of this inhibitor to reduce non­
myofibrillar protein degradation. It has been suggested that calpeptin (ZLnL) is a more 
effective inhibitor of m-calpain (IC50 < 0.1 MM) than of proteasomes (IC50 > 100 MM; 
Figueiredo-Pereira et al., 1994a), and CA has the same potency as calpeptin on calpain and 
proteasome activities. Recently, Hick and Riezman (1996) reported that ubiquitinated cell 
membrane receptor is the target for lysosomal degradation rather than proteasomal 
degradation. In this study, CA (25[IM) caused accumulations of ubiquitinated proteins in L8 
cells after 6 hours incubation. This indicates that calpeptin analogue can prevent degradation 
of ubiquitin-protein conjugates. Similar result was reported in HT4 neuronal cells incubated 
with 50 µM of CA for 3 hours (Figueiredo-Pereira et al., 1994b). CA, which inhibit calpains, 
cathepsin L, and perhaps the proteasome, did not cause a strong stabilization of 
myofibrillar-protein fraction of L8 myotubes. 
Lactacystin is a potent proteasome-specific inhibitor. It reduced TPD by 16% and 
26% at 1 IA1 and 10 MM, respectively. However, it did not significantly stabilize myofibrillar 
proteins. This inhibitor is probably the most specific non-endogenous proteasome inhibitor 
among all which have been found (Fenteany et al., 1995). Concentrations of lactacystin 
above 10 µNI usually caused cell detachment (assessed only by visualization under 47 
microscope). The smaller effect of lactacystin on TPD and its stronger cytotoxicity 
compared with other inhibitors may be due to the high specificity of lactacystin and the 
crucial roles of the proteasome in maintaining normal cell functions. 
Among all inhibitors tested, ZIE(OtBu)AL-CHO (ZIE) exerted the most potent protease 
inhibition activity. ZIE at 0.1, 1, 10, 25 p.M, caused 26%, 44%, 520./0, and 53% reductions in 
TPD, respectively. ZIE had strong inhibitory activity to proteasome (IC50 = 0.25 pM) and 
relatively strong activity against calpain (IC50= 4 gM; Figueiredo-Pereira et al., 1994a). ZIE 
also significantly stabilized myofibrillar protein fraction by 26% when added to culture 
media at 10 1.11\4. 
It is generally agreed that calpain inhibitor-II (CI-II) has a strong inhibitory activity 
against calpains and cathepsins. Yet, it is still uncertain this inhibitor also influences 
proteasome's proteolytic activity or not. Rock et al. (1994) exerted that CI-II demonstrated 
moderate inhibitory activity against the chymotrypsin-like activity of the 20 S proteasome 
(Ki = 1.0 iiM), but had a lower ability to inhibit the 26 S proteasome (Ki = 28 MM). In 
addition, CI-II did not inhibit the production of antigenic peptides of the proteasome (Rock 
et al., 1994). Other investigators suggested that CI-II has a fairly strong inhibitory activity 
against chymotrypsin-like activity and BrAAP activity of the proteasome (Figueiredo-
Pereira et al., 1994a; Orlowski et al., 1993). 
It is worth noting that these experiments were done by testing proteolytic activities 
on different synthetic substrates, which makes summary of current knowledge regarding 
inhibitors and actual functions of proteases difficult. Here we demonstrated by Western blot 
analysis using the concentration of CI-II which reduced TPD and stabilized myofibrillar­
protein portion, that CI-II did not cause accumulation of ubiquitinated-protein complex in 48 
L8 myotubes. This indicates that CI-II may not halt proteasome proteolytic activities under 
physiological conditions. 
Previous studies in our lab showed CI-II, and chloroquine (CQ) decreased TPD 
strongly and moderately, respectively. Only CI-II showed stabilization of myofibrillar 
protein, CQ did not show effect on this pool (Ou, 1995). Chloroquine is a weak base known 
to accumulate in lysosomes immediately after its administration in cultured cells and disable 
the ability of lysosomal cathepsins (De Duve et al., 1974). This makes it a very specific 
lysosomal enzyme inhibitor. 
There is no strong evidence which supports the belief that lysosomal enzymes are 
important in myofibrillar protein turnover. Yet, considerable evidence indicates the 
importance of the proteasome to myofibrillar protein breakdown. Most of the data which 
indicates that the proteasome is involved in myofibrillar protein degradation is based on 
observations that proteasome subunit mRNAs or activity of the proteasome are increased 
when degradation is increased. For examples, Mykles and Haire (1995) found that in lobster 
muscle, heat-shock activating BrAAP activity of the proteasome is responsible for initial 
degradation of myofibrillar proteins. Several studies on muscle wasting have also 
demonstrated that the proteasome system responds more prominently than calpains and 
cathepsins (England, and Price,1995; Temparis et al., 1994; and Llovera et al, 1994). For 
example, Medina et al. (1995) and Wing et al (1995) found that under starvation and 
denervation stress in rat skeletal muscle, the content of Ub-conjugated proteins increased 
50-250%. Total mRNA amount decreased yet proteasome mRNA amount increased. 
Table 3 illustrates inhibitors' specificities to intracellular proteases and actions in L8 
cultured cells. The real intracellular event may not truly reflect in vitro analysis. CI-II tested 49 
in some studies has shown inhibited proteasome fairly strong ((Figueiredo-Pereira et al., 
1994a; Orolwski et al, 1993), but in our study it did not cause accumulations of 
ubiquitinated-protein conjugates. This is more in accord with the result of Rock et al. (1994) 
that CI-II is only a weak inhibitor to proteasome. Most of the data regarding the potency and 
specificities of inhibitors toward a certain proteases are determined in vitro. Results are 
usually expressed as Ki and IC50, representing the affinity between inhibitor and its substrate 
(Ki) and the concentration of inhibitor needed to inhibit 50% of enzyme activity (IC50), 
respectively. The assays involve using fully activated enzymes and provision of synthetic 
substrates for characterization of specificities. These situations do not occur intracellularly, 
so that cautions need to be taken when interpreting inhibitors' effects on intracellular events. 
Results obtained in this project provides strong evidence that the calpains are more 
important to myofibrillar protein degradation than other intracellular proteases. First, 
inhibitors which inhibit calpain and proteasome (e.g. CI-II and ZIE) inhibit myofibrillar 
protein degradation where as lactacystin, a proteasome-specific inhibitor, did not reduce 
myofibrillar protein degradation. Similar results have been obtained in a previous study (Ou, 
1994), inhibitors which inhibit calpain and lysosomal cathepsins (e.g., CI-II; and CA in this 
study) inhibit myofibrillar protein degradation; however, the lysosome-targeting inhibitor 
chloroquine, had no effect on myofibrillar protein degradation. 
Unfortunately, a truly calpain-specific inhibitor has not yet been developed to allow 
us to unequivocally evaluate the specific role of calpains in this process. We had hoped that 
PD150606 would serve this function. However, it did not function as an inhibitor in muscle 
cells. 50 
Evidence that CI-II exerts its effect via calpains is that it did not cause accumulations 
of polv-ubiquitinated proteins whereas other inhibitors did.  This suggests that CI-II­
dependent inhibition of calpains slows myofibrillar protein degradation. Table 3. Specificities and actions of inhibitors 
This table lists the inhibitors action toward three proteolytic system; Y, yes  there is strong to medium inhibitory been observed;
 
N, no  no or weak inhibitory been observed;
 
: unknown
 
The ability to cause accumulation of Ub-proteins of various inhibitor Big solid circle : strong effect, about 3  10 fold of control; 
Small solid circle 0: weak effect, about 1.5  2 fold of control;  : unknown. 
Comparison of inhibitors' maximal effects on total protein concentration (TPD) and myofibrillar proteins (myo). Big solid circle 
: reduction or induction is more than 30% ; Small solid circle : reduction or induction is between 20%-30%; Small open circle 
o: reduction or induction is between 10%-20%; Big open circle 0: reduction or induction is nonsignificant.;  myo-: myofibrillar 
protein fraction. 
inhibitor  inhibit  inhibit calpain  inhibit cathepsin  accumulate Ub- maximal reduction  maximal stabilization 
proteasome  protein  in TPD  in myo-
CA  Y  Y  Y  o 
CI-II  Y  Y  Y  o 
ZIE  Y  Y 
LACT  Y  N  N  0 
CQ  Y  0 CONCLUSION 
Calpain is crucial for myofibrillar breakdown, by limited-cutting of myofibrils and 
release of myofibrillar structures into the cytosol for further degradation by other proteases. 
The blockage of calpain proteolytic pathway causes a strong inhibition of myofibrillar 
protein degradation; while the blockage of other proteolytic pathways, result in only 
moderate to weak/none effects on myofibrillar proteins. 
Calpains though may be responsible for the initial step of myofibrillar protein 
degradation, from much evidence that proteasome respond accordingly to physiological 
changes suggests that it is important to adaptation to stress, probably functioning as an 
enzyme system which processes fragments of myofibrils which are released by calpains. It is 
reasonable to have two regulatory points for myofibrillar protein degradation: calpains could 
regulate the initial step of myofibril break-down, to produce a pool of easily-releasable 
myofibrils. The second regulatory point may degrade the easily-releasable myofibrillar pool 
for the generation of amino acids. 53 
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